Selective Janus kinase inhibitors: Promising drugs for rheumatoid arthritis

被引：1
作者：
Zanwar, Abhishek [1 ]
Aggarwal, Amita [1 ]
机构：
[1] Sanjay Gandhi Postgrad Inst Med Sci, Dept Clin Immunol & Rheumatol, Lucknow, Uttar Pradesh, India
来源：
NATIONAL MEDICAL JOURNAL OF INDIA | 2019年 / 32卷 / 02期
关键词：
TOFACITINIB; ADALIMUMAB; PLACEBO; SAFETY;
D O I：
10.4103/0970-258X.275350
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：96 / +
页数：2
相关论文
共 50 条
  • [41] Cardiovascular, cancer, and infection risks of Janus kinase inhibitors in rheumatoid arthritis and ulcerative colitis: A nationwide cohort study
    Cho, Yongtai
    Yoon, Dongwon
    Khosrow-Khavar, Farzin
    Song, Minkyo
    Kang, Eun Ha
    Kim, Ju Hwan
    Shin, Ju-Young
    JOURNAL OF INTERNAL MEDICINE, 2025, 297 (04) : 366 - 381
  • [42] Number needed to treat and cost per responder of Janus kinase inhibitors approved for the treatment of moderate-to-severe rheumatoid arthritis in Japan
    Atsumi, Tatsuya
    Asakura, Eri
    Doi, Michio
    Sawant, Ruta
    Kawaguchi, Isao
    Sasaki, Nobuhito
    Liew, Danny
    MODERN RHEUMATOLOGY, 2023, 33 (01) : 54 - 63
  • [43] Evaluation of Real-World Evidence to Assess Effectiveness Outcomes of Janus Kinase Inhibitors for Rheumatoid Arthritis: A Systematic Review of US Studies
    Gandy, Chandler
    Bazzazzadehgan, Shadi
    Bruera, Sebastian
    Huang, Yinan
    DRUG HEALTHCARE AND PATIENT SAFETY, 2025, 17 : 25 - 49
  • [44] Cost-effectiveness of janus kinase inhibitors for rheumatoid arthritis: A systematic review and meta-analysis of cost-utility studies
    Kumar, S. Sajith
    Haridoss, Madhumitha
    Venkataraman, Krishnamurthy
    Bagepally, Bhavani Shankara
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [45] Janus kinase inhibitors clear to land Janus kinase inhibitors in RA
    Aringer, Martin
    RHEUMATOLOGY, 2018, 57 (07) : 1131 - 1132
  • [46] Biologic disease-modifying anti-rheumatic drugs and kinase inhibitors: differences in efficacy and safety in rheumatoid arthritis
    Fleischmann, Roy
    CLINICAL RHEUMATOLOGY, 2021, 40 (11) : 4369 - 4372
  • [47] Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis
    Weng, Chenghua
    Xue, Leixi
    Wang, Qing
    Lu, Wentian
    Xu, Jiajun
    Liu, Zhichun
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
  • [48] A comparison of Janus kinase inhibitor safety in rheumatoid arthritis
    Nash, Peter
    Lim, Irwin
    Marabani, Mona
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2021, 24 : 3 - 14
  • [49] Comparison of active tuberculosis occurrence associated with Janus kinase inhibitors and biological DMARDs in rheumatoid arthritis
    Song, Yun-Kyoung
    Lee, Jaehee
    Jo, Junwoo
    Kwon, Jin-Won
    RMD OPEN, 2024, 10 (02):
  • [50] Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study
    Ebina, Kosuke
    Etani, Yuki
    Maeda, Yuichi
    Okita, Yasutaka
    Hirao, Makoto
    Yamamoto, Wataru
    Hashimoto, Motomu
    Murata, Koichi
    Hara, Ryota
    Nagai, Koji
    Hiramatsu, Yuri
    Son, Yonsu
    Amuro, Hideki
    Fujii, Takayuki
    Okano, Takaichi
    Ueda, Yo
    Katayama, Masaki
    Okano, Tadashi
    Tachibana, Shotaro
    Hayashi, Shinya
    Kumanogoh, Atsushi
    Okada, Seiji
    Nakata, Ken
    RMD OPEN, 2023, 9 (03):
12345